Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) just unveiled an update.
WuXi AppTec has proposed the re-election of its current executive and non-executive directors as the term of the third session of its board approaches expiry in May 2026. The company plans to seek shareholder approval at the 2025 annual general meeting to renew three-year terms for key executives, including chairman and CEO Dr. Ge Li, and to maintain continuity in board leadership and governance structures.
The proposals also cover the re-election of non-executive directors and the alignment of their remuneration with the overall board compensation framework to be approved at the same meeting. If endorsed, WuXi AppTec will enter into new letters of appointment with these directors, signaling a focus on stability in strategic oversight, which may reassure investors amid ongoing sector and regulatory developments in the Chinese biopharmaceutical services market.
The most recent analyst rating on (HK:2359) stock is a Hold with a HK$124.00 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.
More about WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. is a China-based joint stock company operating in the pharmaceutical and life sciences service industry. The company provides research, development and manufacturing services to global biopharmaceutical customers, and its leadership also has ties to related entities such as WuXi Biologics, underscoring its role in the broader biotech outsourcing ecosystem.
Average Trading Volume: 4,883,675
Technical Sentiment Signal: Buy
Current Market Cap: HK$303.7B
Find detailed analytics on 2359 stock on TipRanks’ Stock Analysis page.